NCT04525781

Brief Summary

To pinpoint the clinical ,epidimiological factors and clinical outcomes in urinary bladder cancer patients attending to our department during 5 years period between 2015-2019.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 25, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

August 25, 2020

Status Verified

August 1, 2020

Enrollment Period

1 year

First QC Date

August 20, 2020

Last Update Submit

August 24, 2020

Conditions

Urinary Bladder Cancer

Outcome Measures

Primary Outcomes (1)

  • comparison of response in non muscle invasive,muscle invasive and metastatic bladder cancer.

    Analysis of patients data including risk factors and treatment and detection of response in each stage.

    baseline

Secondary Outcomes (1)

  • Survival in bladder cancer in different stages

    baseline

Study Arms (1)

1

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

study initialy including about 150 patients with urinary bladder cancer.

You may qualify if:

  • age 18 :70
  • Histologically proved urinary bladder carcinoma

You may not qualify if:

  • Age less than 18 or more than 70
  • Patient not documented having bladder carcinoma with biopsy \[cysyoscopic or operative\]
  • Patient with synchronous or metachronous double primary

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (11)

  • Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.

    PMID: 15761078BACKGROUND

  • Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016 Feb;69(2):300-10. doi: 10.1016/j.eururo.2015.08.037. Epub 2015 Sep 4.

    PMID: 26346676BACKGROUND

  • Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007 Jun;25(3):285-95. doi: 10.1007/s00345-007-0168-5.

    PMID: 17530260BACKGROUND

  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.

    PMID: 25220842BACKGROUND

  • Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015 Apr;29(2):177-89, vii. doi: 10.1016/j.hoc.2014.10.001.

    PMID: 25836927BACKGROUND

  • Zhao M, He XL, Teng XD. Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin J Cancer Res. 2016 Feb;28(1):92-8. doi: 10.3978/j.issn.1000-9604.2016.02.05.

    PMID: 27041931BACKGROUND

  • Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. doi: 10.3322/canjclin.55.1.10.

    PMID: 15661684BACKGROUND

  • Lynch CF, Cohen MB. Urinary system. Cancer. 1995 Jan 1;75(1 Suppl):316-29. doi: 10.1002/1097-0142(19950101)75:1+3.0.co;2-t.

    PMID: 8001003BACKGROUND

  • Golka K, Wiese A, Assennato G, Bolt HM. Occupational exposure and urological cancer. World J Urol. 2004 Feb;21(6):382-91. doi: 10.1007/s00345-003-0377-5. Epub 2003 Nov 26.

    PMID: 14648102BACKGROUND

  • Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer. 1986 Mar;53(3):399-405. doi: 10.1038/bjc.1986.65.

    PMID: 3964542BACKGROUND

  • Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004 Jan;93(2):216-20. doi: 10.1111/j.1464-410x.2004.04588.x.

    PMID: 14690486BACKGROUND

Related Links

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Central Study Contacts

Rehab Osama Abdelmoboud

CONTACT

01064482770Rehabosama620@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 20, 2020

First Posted

August 25, 2020

Study Start

October 1, 2020

Primary Completion

October 1, 2021

Study Completion

December 1, 2021

Last Updated

August 25, 2020

Record last verified: 2020-08